Wolfgang Miesbach Highlights CRISPR-Cas9 Off-Target Safety in Human Genome Editing
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on X:
“՛CRISPR-Cas9 Clinical Safety: Off-Target Assessment Framework — A recently published review highlights the need for advanced strategies to address off-target effects, the most significant challenge in therapeutic genome editing.
CRISPR-Cas9 Overview
CRISPR-Cas9 uses programmable nucleases comprising Cas9 endonuclease and guide RNA (gRNA) to create targeted double-strand breaks with base-pair precision. Current therapeutic applications include treating β-hemoglobinopathies via BCL11A enhancer targeting, demonstrated by Casgevy—the first FDA-approved CRISPR therapy.
Off-Target Effects -Critical Safety Challenge
Off-target activity occurs when CRISPR-Cas9 cleaves unintended genomic loci, potentially:
- Disrupting tumor suppressor genes or proto-oncogenes
- Generating large structural variants (deletions, inversions, translocations)
- Causing chromosomal instability and potential malignant transformation
Clinical reality: Over 100 active CRISPR clinical trials are underway, yet safety assessment protocols remain inconsistent.
Five-Tier Safety Assessment Framework
The authors propose a clear five-step safety evaluation:
1. Computational gRNA Design
In silico prediction tools identify potential off-target sites
High-fidelity Cas variants reduce off-target binding
2. Experimental Off-Target Nomination
Cell-free and cell-based assays provide genome-wide detection
Orthogonal validation using multiple methodologies
3. Structural Variant Detection
Long-read sequencing identifies large deletions and rearrangements
Digital PCR quantifies specific variants with high sensitivity
4. Functional Safety Assessment
In vitro transformation assays evaluate oncogenic potential
Single-cell sequencing links genotype to phenotype
5. Regulatory Compliance
GMP-grade manufacturing ensures consistent quality
FDA/EMA guidelines mandate comprehensive characterization
Personalized Safety Considerations
Population-specific variants can create or eliminate off-target sites. Solution: Variant-aware prediction tools incorporate individual genetic profiles to identify population-specific or patient-specific risks.
The Path Forward
Standardizing rigorous safety frameworks while maintaining innovation pace remains the key challenge. As CRISPR transitions from experimental tool to clinical standard, comprehensive off-target assessment becomes scientifically essential and ethically imperative for patient safety.
Congratulations to Nechama Kalter and co-authors.”
Read the full article here.
Title: Off-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges
Authors: Nechama Kalter, Carla Fuster-García, Alfredo Silva, Víctor Ronco-Díaz, Stefano Roncelli, Giandomenico Turchiano, Jan Gorodkin, Toni Cathomen, Karim Benabdellah, Ciaran Lee, Ayal Hendel
Stay updated on the latest scientific advances with Hemostasis Today.
-
Jan 12, 2026, 14:46A Behcet Disease with Aortic Thrombosis: Alexandru Stieber Shares A Peculiar Case
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies